DUBLIN--(BUSINESS WIRE)--Aug 2, 2018--The “Global Prostate Cancer Diagnostics & Therapy Market - Segmented by Type, Diagnosis, Treatment, and Geography - Growth, Trends, and Forecast (2018 - 2023)” report has been added to ResearchAndMarkets.com’s offering.
The prostate cancer diagnostics market is expected to witness a CAGR of 6.1% during the forecast period (2018-2023). North America was leading the global market with the largest revenue share in 2016.
The high prevalence rate of prostate cancer is a key factor, which is driving the global market for the prostate cancer. Prostate cancer is the second-leading cause of death in the United States. According to National Cancer Institute, it is estimated that there were around 161,360 new cases of prostate cancer and an estimated 26,730 people will die due to it.
There are many new drugs that have increased the life expectancy of prostate cancer patients and have been approved by the Food & Drug Administration. But these drugs are having a high cost, which is a threat for the patients and the insurers, both. These expensive drugs are not being paid by the insurance companies and the reimbursement level for them is very low.
North America is the leading global market with the largest revenue share in 2016. Due to the rising prevalence of the diseases and high mortality rate of the prostate cancer in the United States, North America is dominating the market. Asia-Pacific is also projected to be the fastest growing region, due to the improving healthcare infrastructure and the growing investments by the key market players.
Companies MentionedAbbott Astrazeneca Astellas Pharma Inc. Bayer Ag Biomark Diagnostics Inc. Sanofi Ipsen Tolmar Pharmaceuticals Inc. Indevus Pharmaceuticals Inc. Dendreon Inc. Ferring Bv Cellanyx Llc
Key Topics Covered:
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
7. Market Segmentation
8. Competitive Landscape
9. Key Players
10. Future of the Market
For more information about this report visit https://www.researchandmarkets.com/research/rs6v4w/global_prostate?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180802005492/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Diagnostics,Prostate Cancer Drugs
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 08/02/2018 09:45 AM/DISC: 08/02/2018 09:45 AM